Journal
JOURNAL OF THORACIC DISEASE
Volume 9, Issue 11, Pages 4700-4707Publisher
AME PUBL CO
DOI: 10.21037/jtd.2017.10.111
Keywords
Idiopathic pulmonary fibrosis (IPF); interstitial lung diseases (ILDs); therapeutics; dyspnea; cough
Categories
Ask authors/readers for more resources
Idiopathic pulmonary fibrosis (IPF) is the most common cause of interstitial lung disease (ILD) and carries a worse prognosis than many cancers. Until recently, there were no active treatment options available for patients with IPF, meaning palliation or lung transplantation in selected patients were the only options. The management of IPF has changed dramatically over the last decade with the advent of two antifibrotic agents; pirfenidone and nintedanib. These new agents have been shown to reduce decline in lung function and pirfenidone has been shown to reduce mortality. The changing landscape of IPF diagnosis and management present a number of issues that may be encountered including management of side effects related to antifibrotic therapy. This article aims to give an overview of the holistic approach to the management of patients with IPF, including antifibrotic management, symptom management and the invaluable role of the ILD specialist nurse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available